Pharmaceutical co-development services

Protagen specializes in Pharma development services in the fields of immuno-oncology and autoimmune disease. Via co-development projects with its strategic partners, Protagen enables effective, targeted immuno-therapeutic development for improved patient care.

Protagen is a lab services business that is at the forefront of immuno-profiling and the discovery of novel biomarkers for immuno-oncology, autoimmune disease, and other immune-driven diseases. Using its proprietary immuno-profiling platform (SeroTag®), and stratification arrays based on biomarker panels (NavigAID) to screen patient serum specimens, Protagen is able to provide:

  • Better disease activity assessment
  • Improved response prediction
  • Patient monitoring
  • The early detection of immune-related adverse events (irAEs)

Find out why Protagen is engaged by 5 of the top 10 pharma.


Immunotherapies hold great promise for treating cancer but only work effectively on a small subset of patients. Protagen supports effective immunotherapy development via its SeroTag® platform to improve therapeutic outcomes and reduce adverse side effects.


NavigAID SLE is a stratification tool which separates and defines subgroups of Systemic Lupus Erythematosus (SLE) patients, to overcome heterogeneity and enable new approaches to successful drug development.

NavigAID SSc

NavigAID SSc, is a new disease stratification array for Systemic Sclerosis (SSc), developed to separate and define disease-specific subgroups to improve disease activity assessment and response prediction for effective drug development.

SeroTag platform and NavigAID pipeline

Protagen is uniquely positioned via its SeroTag® platform, to combine the largest library of human proteins with the high-throughput identification of disease and treatment markers, to develop more effective diagnostics and companion diagnostics.